General MedicationsORALGeneric
RESCRIPTOR
DELAVIRDINE MESYLATE
Standard Dose
200MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: 901 REQUIRED Marketing status: Discontinued
Summary
Approval overview RESCRIPTOR is listed in Drugs@FDA under application 020705 (NDA).
Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient DELAVIRDINE MESYLATE Form and strength TABLET;ORAL - 200MG Sponsor VIIV HLTHCARE Submission history Latest submission status date: 2012-08-10 00:00:00.
Structured Monograph
Clinical summary
Approval overview RESCRIPTOR is listed in Drugs@FDA under application 020705 (NDA). Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient DELAVIRDINE MESYLATE Form and strength TABLET;ORAL - 200MG Sponsor VIIV HLTHCARE Submission history Latest submission status date: 2012-08-10 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: 901 REQUIRED
Interaction Notes
- No interaction notes stored yet.